Following a transformative year in 2025, marked by validation of its PROBODY masking platform, CytomX Therapeutics Inc. (CTMX) is positioning its two clinical-stage programs for key upcoming data readouts.
The company's PROBODY therapeutic platform is designed to enable a more targeted approach to cancer treatment. PROBODY therapeutics are engineered to bind preferentially to tumor tissue while limiting activity in healthy tissue. This selectivity is achieved through a proprietary masking mechanism that temporarily blocks the therapy's target-binding region, thereby reducing activity in normal tissues.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.